BRIEF published on 11/12/2025 at 07:05, 22 days 23 hours ago Springer Nature Reports Robust Growth in Early 2025 Financial Results Revenue Growth Springer Nature 2025 Guidance Research Segment
PRESS RELEASE published on 11/12/2025 at 07:00, 22 days 23 hours ago Strong business performance in the first nine months of 2025. Full Year 2025 guidance reiterated Springer Nature reports strong business performance in the first nine months of 2025, including revenue growth in research and operational profit. Full-year 2025 guidance reaffirmed Revenue Growth Operating Profit Business Performance 2025 Springer Nature
BRIEF published on 08/13/2025 at 07:05, 3 months 22 days ago Springer Nature Sees Robust Growth in H1 2025 AI Development Open Access Springer Nature Research Segment 2025 Revenue Growth
PRESS RELEASE published on 08/13/2025 at 07:00, 3 months 22 days ago Springer Nature reports strong growth in the first half of 2025 and raises full-year guidance Springer Nature reports strong growth in the first half of 2025 with 6% revenue increase and 10% adjusted operating profit growth. Full-year guidance raised Revenue Operating Profit Growth Guidance Springer Nature
BRIEF published on 08/12/2025 at 18:57, 3 months 23 days ago Springer Nature Raises 2025 Guidance Amid Strong Performance Revenue Growth Financial Performance Springer Nature 2025 Guidance Research Segment
PRESS RELEASE published on 08/12/2025 at 18:52, 3 months 23 days ago EQS-Adhoc: SPRINGER NATURE AG & Co. KGaA: Springer Nature raises guidance for the full year 2025 Springer Nature raises guidance for 2025 fiscal year, expecting higher revenue and adjusted operating profit due to strong performance. Results to be released on Aug 13, 2025 Revenue Operating Profit Guidance Springer Nature 2025 Fiscal Year
BRIEF published on 05/13/2025 at 07:05, 6 months 22 days ago Springer Nature Announces Solid Start to 2025 Financial Year Revenue Growth Technology Investment First Quarter 2025 Open Access Springer Nature
PRESS RELEASE published on 05/13/2025 at 07:00, 6 months 22 days ago Springer Nature reports strong start to 2025 Springer Nature reports strong start to 2025 with 6% revenue growth and 11% increase in adjusted operating profit. Focus on Research and Open Access initiatives Revenue Growth Research 2025 Open Access Springer Nature
BRIEF published on 03/18/2025 at 07:05, 8 months 17 days ago Springer Nature's 2024 Financial Success and 2025 Growth Projections Revenue Growth 2024 Financial Results Springer Nature 2025 Projections Open Access Journals
PRESS RELEASE published on 03/18/2025 at 07:00, 8 months 17 days ago Springer Nature achieves revenue and profit targets and projects further growth for 2025 Springer Nature achieves revenue and profit targets for 2024, with 5% revenue growth to €1,847 million. Focus on tech & AI applications and 50% OA research articles published Revenue Springer Nature Profit Targets Tech & AI OA Research
Published on 12/05/2025 at 02:35, 3 hours 51 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 26 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 21 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 26 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 2 hours 56 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 35 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 1 minute ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 11 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 16 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 12 hours 26 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 41 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 42 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 25 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago Declaration of voting rights at the end of November 2025
